Compare GTY & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTY | AUPH |
|---|---|---|
| Founded | 1955 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1998 | 2014 |
| Metric | GTY | AUPH |
|---|---|---|
| Price | $33.07 | $15.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $32.60 | $17.25 |
| AVG Volume (30 Days) | 334.1K | ★ 1.2M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.92% | N/A |
| EPS Growth | 8.00 | ★ 5075.00 |
| EPS | ★ 0.43 | 0.25 |
| Revenue | $221,727,000.00 | ★ $283,055,000.00 |
| Revenue This Year | $9.39 | $17.54 |
| Revenue Next Year | $7.83 | $15.74 |
| P/E Ratio | $76.70 | ★ $63.36 |
| Revenue Growth | 9.02 | ★ 20.38 |
| 52 Week Low | $25.39 | $7.29 |
| 52 Week High | $34.75 | $16.88 |
| Indicator | GTY | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.82 | 54.94 |
| Support Level | $32.44 | $14.53 |
| Resistance Level | $33.99 | $16.29 |
| Average True Range (ATR) | 0.66 | 0.54 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 72.84 | 60.52 |
Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.